In SELECT, semaglutide 2.4 mg subcutaneously weekly reduced MACE by 20% (HR 0.80, 95% CI 0.720.90) with a 1.5% absolute risk reduction over a mean follow-up of 39.8 months [3]
Authors were contacted if not enough data was included in the original manuscript for analysis, for clarification of terms or to confirm whether the article contained data previously published by the same research group
News of the benefits spread by word of mouth and social media, with patients and doctors sharing click-charts with dosage recommendations
Understanding these mechanisms could lead to targeted treatments for diabetes-related cognitive dysfunction
Enjoy radiant, even-toned, and smoother skin with Selmax Derma Nature Glutathione Cream , which combines instant brightening, intensive care, and genuine support for skin health